TP53 and colorectal carcinoma: It is also important to highlight the need of identifying TP53 somatic mutations in CRC patients, since it has been shown that tumors could be resistant to classical chemotherapies, and some authors have proposed that TP53 mutants are a suitable target for immunotherapies [20].